Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases. The company is developing two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.